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Te current severe acute respiratory syndrome coronavirus 2
testing policy and practice limits testing as a prevention tool.
Radical shifs are required to increase the scale of rapid testing
strategies and improve dissemination and implementation of
venue-based and self-testing approaches. Attention to the full
translation pipeline is required to reach high-risk segments of
the population.
Keywords.
dissemination; reach; SARS-CoV-2; testing;
translation.
OVERVIEW

The current paper discusses the importance of understanding
severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) self-testing in the broader context of translating testing
innovations to real-world settings. Our perspective is that
self-testing should be an integral part of a larger venue-based
testing system; self-testing is not a replacement for venue-based
testing, it is an enhancement that increases system reach to include individuals who desire testing but have limited or no access to venue-based testing (eg, clinic or drive-through sites).
We recognize that there are segments of the population who,
for a variety of reasons, are resistant to testing just as they deny
the existence of a pandemic or espouse antivaccine beliefs. Our
discussion does not address this latter population segment.
Service [1] summarized expert opinion and recent studies in
concluding that stemming the spread of SARS-CoV-2 requires
a radical change in testing policy and practice including the following: (1) substantial increases in support for scaling up test
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production, (2) using tests that produce results more rapidly,
and (3) increasing the frequency of testing (eg, testing every
2–4 days) to allow for the use of less sensitive, but more available
tests, and to reduce the spread of SARS-CoV-2 by shortening
the length of time between initial infection, test results, and preventive action. Although we concur with these proposed policies, it is critical to more fully address the translation pipeline
including test dissemination and consumer implementation
with attention to reaching high-risk populations (eg, Latinos,
African Americans, American Indian/Alaska Native, Native
Hawaiian/Pacifc Islander, low literacy adults, adults with poor
mobility, and low healthcare access) [2, 3]. Furthermore, we
agree that SARS-CoV-2 self-testing has the potential to (1) augment prevention eforts by increasing the frequency of repeat
testing over short periods of time, (2) reduce access barriers
to testing (eg, for low income, elderly, mobility challenged; ie,
transportation barriers signifcantly reduce healthcare seeking)
[4, 5], (3) decrease health risks associated with venue-based
testing (eg, viral exposure from/to others), (4) reduce SARSCoV-2 healthcare costs by reducing the need for contact with
trained providers, and (5) improve linkage to care through
earlier detection.
SEVERE ACUTE RESPIRATORY SYNDROME
CORONAVIRUS 2 SELF-TESTS: STRENGTHS AND
LIMITATIONS

There is considerable precedence for self-testing as a mechanism for increasing monitoring (eg, blood pressure, blood
glucose self-testing) and for strengthening primary/secondary
prevention efforts (eg, human immunodeficiency virus [HIV],
pregnancy home testing). Past work suggests that self-testing
has the greatest potential for widespread adoption when the
costs are low, tests are widely available and easy to access, tests
are simple and/or painless to self-implement, and results are
rapidly obtained [6–9].
Currently, there are 3 ways to test for SARS-CoV-2: antibody,
antigen, and ribonucleic acid (RNA)-based tests. Antigen and
RNA-based tests provide information on active infections. Both
are highly specifc, but RNA-based tests are more sensitive. Te
RNA-based polymerase chain reaction (PCR) tests are considered
to be the gold standard for providing defnitive results on active
infections. Tere are multiple SARS-CoV-2 RNA-based PCR
self-testing strategies [10–13] that allow for home self-collection
of oral or nasal specimens, which are returned to a laboratory for
analysis. Past work suggests that RNA-based tests may generate
errors in identifying active infection because the test is unable to
discriminate between live and dead virus [14]. Moreover, RNAbased tests do not provide information on past infection.
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From a dissemination implementation perspective, the major
limitations of RNA-based PCR self-tests are their expense (>$100)
and associated delays in obtaining results. Te overall process requires 3 steps: (1) the test is ordered and delivered, (2) the consumer performs the test and mails it back to the laboratory, and
(3) the laboratory performs the testing procedures and returns the
test results. Tis 3-step process may take 4–6 days to complete. In
some rare circumstances, this process may take longer due to delays in acquiring or returning specimen collection kits. Processing
of self-test specimens typically occurs at national laboratories.
Manufacturers (eg, LabCorp) [10] estimate that laboratory specimen analysis alone will take 1–2 days. Moreover, specimens that
are delayed in arriving at the laboratory may be rejected, which
requires a new specimen collection by the consumer.
However, a signifcant improvement in RNA-based selftesting has recently occurred (November 17, 2020) with the US
Food and Drug Administration (FDA) approval of the Lucira
coronavirus disease 2019 (COVID-19) complete all-in-one
at-home test kit (ie, home specimen collection, analysis, and results). Tis is a single-use test kit intended to detect active infection using the loop-mediated isothermal amplifcation method
(LAMP) to detect viral RNA [15]. Although this test could conceivably be a major step forward in home-testing, it requires a
prescription from a physician and costs approximately $50 per
test. Te prescription requirement will potentially reduce the
reach of this home test kit to (1) those individuals who are experiencing symptoms and have a physician and (2) those who
have insurance coverage. Consequently, low-income individuals without insurance and who do not have a regular physician
(eg, rural Latino farmworkers) may have difculty accessing
this test [16].
Full at-home antigen tests are not yet available but are under
development [17]. Current antigen tests, such as Abbott’s Binax
NOW rapid COVID-19 antigen test, are point-of-service tests
that require an expensive device to test specimen samples.
Consequently, it is not an at-home testing procedure, but a
venue-based testing method, although it could be coupled with
mobile testing services to improve reach to less mobile communities. Te challenge with antigen tests is that specimens collected beyond 5–7 days afer the onset of symptoms may reduce
sensitivity and produce a higher rate of false negative results.
Antibody testing informs an individual that they have been
infected but does not identify persons with active infections
who are capable of spreading SARS-CoV-2. Medek has produced the Healgen COVID-19 antibody test, which can generate results at home (ie, specimen collection, analysis, and test
results are obtained at home) in approximately 10 minutes [18].
Tis test has value for surveillance and behavioral epidemiological studies because it helps to identify pathways that SARSCoV-2 infection has taken in the population.
Research to date on SARS-CoV-2 self-tests has primarily
emphasized accuracy and manufacturing capacity [1, 17, 19],
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with less focus on how to improve dissemination and implementation in high-risk population segments. Current SARSCoV-2 self-testing strategies are expensive [17], dissemination
is primarily internet-based, and may be poorly adapted for lowliteracy, non-English speaking adults.
SELF-IMPLEMENTATION CHALLENGES

Self-implemented health practices require that the consumer
receive training materials that are easy to comprehend and to
use. With respect to SARS-CoV-2 self-testing, implementation
fidelity studies need to be conducted with consumers in natural
settings rather than clinical settings to verify that the materials
being used to train consumers in self-implementation are able
to do that correctly (ie, consumers comprehend training materials and perform required test procedures correctly). The SARSCoV-2 self-tests more often use written and graphic inserts and
less frequently use online videos as training materials. These materials need to be examined closely, particularly in low-literacy
populations that might have trouble understanding written or
graphic instruction materials. Prior investigations [20, 21] have
not reported self-test performance fidelity for those who are less
likely to perform self-testing correctly (eg, low income, less educated persons) or for high-risk segments of the population (eg,
low-income African American or Latino persons) (eg, Tu et al
[21] do not report race/ethnicity data; Altamirano [20] reports
data for only 2 Latino cases and reports no education data).
Moreover, these studies do not examine training materials and
self-implementation in natural settings outside of the clinical
environment. Parallel literature on implementation fidelity for
HIV oral self-testing may be helpful to investigators pursuing
SARS-CoV-2 self-testing research (see “Lessons From Human
Immunodeficiency Virus Testing” below).
DISSEMINATION CONCERNS

We agree with Service [1] in pointing out how critical it is to
reduce the lag time between consumers test-seeking and receiving results; in this context, we believe that improvements
in dissemination of at-home testing can reduce lag time [17].
Reducing lag time may have important treatment ramifications.
Delays incurred could make a difference in whether life-saving
interventions can be administered and may negatively impact
clinical outcomes (eg, remdesivir is more effective when oxygenation requirements are minimal) [22].
With regards to dissemination, the majority of current SARSCoV-2 testing is being conducted through venue-based approaches wherein people need to access a clinic or other venue
(eg, drive-through sites) to obtain testing. Te limits of venuebased health practices have been documented in other contexts
(eg, problems reaching African Americans [6–8] at high risk
for HIV infection and limiting vaccine dissemination to Latino

workers whose access is inhibited by the absence of sick leave
that would allow them to seek medical services [16]).
As noted earlier, internet dissemination of SARS-CoV-2 selftesting may limit access. Internet-based dissemination strategies
require a proactive individual who has access to the internet.
Despite the popular myth that everyone has internet access (ie,
either computer or cellphone), US census data reveals that access is signifcantly lower for low-income and ethnic/racial minority persons [23, 24], population segments at high-risk for
SARS-CoV-2. With regard to self-testing, we recommend dissemination through commercial sites (eg, pharmacies, grocery
stores), community-based organizations (without prescription), and mobile test units (eg, health van delivery of testing to
specifc neighborhoods, rural areas) that increase reach to highrisk communities. Mobile testing ofers a unique advantage in
that it has proven to successfully improve access to healthcare
for high-risk ethnic minority populations [5], and it would
allow dissemination of both venue-based tests and self-test kits.
Mobile SARS-CoV-2 testing units are being deployed in some
states but, to our knowledge, do not include self-testing options
(eg, Texas) [25]. Support is needed at all levels to increase the
production and dissemination of mobile van units devoted to
SARS-CoV-2 testing.
In applying testing as a prevention strategy, it is also important to consider translation with regards to dissemination capacity. In discussing testing as a prevention tool, Service [1]
reviewed work by Paltiel et al [26] which shows that university
settings would need to test everyone every 2–3 days to achieve
a successful prevention strategy. Tis type of strategy would require a large workforce to rapidly and repeatedly disseminate
point-of-service tests or feld workers to administer tests in
students’ residences (eg, 133 full-time staf to test 20 000 students in 3 days). Full at-home self-testing may reduce workforce
problems by allowing students to test themselves frequently, assuming that a sufcient volume of tests are available.
LESSONS FROM HUMAN IMMUNODEFICIENCY
VIRUS TESTING

Human immunodeficiency virus testing has evolved from a
clinic-based testing model to one that encompasses communitybased test sites (eg, churches, street fairs, service organizations)
and self-testing. Although this system has developed over
the past 30 years, the movement from venue-based testing to
self-testing was slow (ie, self-testing was available for almost 1
decade [6, 9], but Centers for Disease Control and Prevention/
state health departments were slow to adopt the tests [7, 8, 27]).
Questions were raised concerning the utility of self-testing to
reach high-priority populations, the ability of individuals to selftest correctly, and whether self-testing would inhibit or facilitate
clinical diagnosis, linkage to care, and counseling. Concerns
regarding HIV self-testing persisted, and venue-based HIV
testing continued to be a priority for prevention and/or linkage

to care [28, 29] despite research identifying the limitations of
this approach in reaching high-risk populations [6, 30].
A major goal of self-testing is to improve the reach of the
testing system to population segments that have difculties or
are reluctant to seek testing from public venues. Evidence that
approximately 15%–20% of new HIV cases were previously unaware of their HIV status [29, 31, 32] suggests that venue-based
testing resources in the United States have limited reach in
some population segments. In particular, venue-based testing
has been demonstrated to have poor reach into high-risk populations in which self-testing is more acceptable [6, 30, 33]. In
this regard, self-implemented HIV testing has gained global
acceptance and has signifcant potential to extend the reach of
HIV testing among priority populations [6–8, 14, 34].
Until recently, oral-HIV self-testing was primarily being disseminated through commercial sites such as pharmacies [6].
Because of this limited distribution process and high commercial costs (>$40 per unit), oral-HIV self-testing had poor dissemination unless underwritten by public funding [6]. Before
the COVID-19 pandemic, HIV self-testing was primarily recommended as a screening test. Since the COVID-19 pandemic
internet dissemination of free oral-HIV self-tests has become
commonplace [27, 35], with departments of public health offering oral-HIV home test kits as a primary test with the proviso
that if individuals test positive and seek pre-exposure prophylaxis, then they would need additional testing [27].
Another criticism of self-testing is that consumers may not
use it even if it is more widely available. A substantial body
of work has shown that oral-HIV self-testing is preferred by
consumers over venue-based testing and fnger-stick HIV
self-testing [6, 14, 27, 35–38]. In this context, we suspect that
SARS-CoV-2 self-testing that involves saliva samples will show
a higher consumer preference over nasal or oral swabs, which
can be uncomfortable.
Studies examining the sensitivity and specifcity of oral-HIV
self-testing in community settings have been mixed. Some
studies have found lower sensitivity for oral-HIV self-test kits
compared with blood-based tests [14, 39], but several other
studies suggest that oral and blood-based tests are equivalent
[9, 40–44]. Catania et al [45] have suggested the challenge is not
with the test itself, but with consumers’ ability to implement the
test with high fdelity. We suspect that COVID-19 self-testing
will also show higher variability in diagnostic accuracy across
samples, in part because of diferences in tests, but also because
tests difer in the challenges they pose for self-implementation.
Another criticism of SARS-CoV-2 self-testing is that people
will not faithfully test themselves [17]. However, such criticisms are somewhat vague and unsubstantiated. Te ability
of self-testing to identify COVID-19 cases to facilitate earlier
quarantine or treatment is an empirical question to which we
do not currently have an answer. However, from the experience of people working in the feld of HIV, we have found that
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individuals can overcome their reluctance to get tested as well
as overcome barriers to venue-based testing through access to
self-testing [7, 8]. Large-scale dissemination studies have shown
the ability of HIV self-testing to reach never-tested populations
[7, 8]. Nevertheless, we assume that there remains a population segment that cannot be reached with either venue-based
or at-home self-tests. From this perspective, we believe that
individuals who are resistant to COVID-19 prevention messages and disbelieve the presence of a COVID-19 pandemic will
probably not get tested, just as they are unlikely to get vaccinated. However, it is specious to argue that we should not widely
disseminate COVID-19 self-tests because some population segments will not participate.
An early concern regarding HIV self-testing was whether it
would improve or inhibit identifcation of HIV cases and, in
turn, if it would be possible to link people to care and/or counseling if they were self-testing at home. In this context, it is important that people self-test frequently to increase the chance
that they can identify a new infection and, in turn, take reasonable action. With HIV self-testing, the FDA required that
at-home self-tests provide the consumer with a link (telephone/
internet) to counselors to aid in the interpretation of test results,
provide necessary prevention information, and direct individuals to treatment sites geographically proximal to their home
residence. Similar comprehensive services should be attached
to SARS-CoV-2 self-testing strategies. Tis type of proactive
service will help produce a potentially seamless link between
self-testing and prevention and/or treatment. In this regard, we
would assume that individuals who seek self-testing will also
be motivated to engage in prevention activities and/or seek
treatment advice.
With regards to improving identifcation of COVID-19 cases
as noted, it is important to increase the frequency of testing
[17]; self-testing can help accomplish this goal. Extensive work
within the feld of HIV has shown that high accessibility and
low cost will increase self-testing frequency, earlier detection of
new infections, and facilitate linkage to care [6–8, 33, 34, 46–
51]. A diagnostic criticism is that only symptomatic individuals
will seek self-testing, and, therefore, it cannot be useful as a true
preventative strategy in that asymptomatic persons who are infected and capable of spreading SARS-CoV-2 will not be identifed. From the feld of HIV, it has been clear for some time that
asymptomatic individuals will test themselves for HIV given
public health messages that motivate asymptomatic persons to
get tested. Self-testing works best in combination with public
health campaigns designed to motivate test uptake [52–54].
A fnal criticism of self-testing strategies is that people may
have signifcant challenges implementing at-home self-test kits.
We agree based on our work in HIV that there are some population segments that may have problems. However, the problem
is not with the tests per se, but with the instructional or training
materials that accompany self-tests. For instance, OraSure’s
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oral-HIV self-test combines graphic and written instructions
along with video instruction that facilitates good training comprehension and performance fdelity, even among less-educated
populations [30, 45, 55]. Video training components need to be
culturally and linguistically appropriate and have been shown
to signifcantly improve implementation fdelity (vs graphic instructions) among populations with low literacy [56]. Te video
component is critical because it supplants the need for reading
and understanding written or graphic instructions. We strongly
recommend more extensive self-implementation studies for
SARS-CoV-2 self-tests in a wider range of populations, particularly those at highest risk for severe COVID-19 outcomes
and for individuals least likely to understand written or graphic
instructions.
CONCLUSIONS

Translation studies are needed in the field of public health to
understand how to improve dissemination and implementation of evidence-based programs or technology in everyday
settings across diverse populations [57]. The present SARSCoV-2 venue-based and self-testing system has challenges with
respect to dissemination, implementation, and reach. There is
an urgent need to conduct studies that examine these issues
particularly among those who are at high-risk for SARS-CoV-2
infection and severe outcomes (eg, low income, elderly persons,
African American, Indigenous, and other people of color) [2,
3]. We need to expand the testing policy-practice framework
to encompass the entire translation pipeline within a multilevel
perspective (ie, multiple dissemination and implementation
pipelines).
We recommend large-scale dissemination of both SARSCoV-2 venue-based testing and self-testing, with the specifc
goal of reaching those persons who are unable to obtain venuebased testing but are motivated to get tested for COVID-19.
Tis process should include increased information dissemination on availability and where to access self-tests to better
inform individuals who are unaware of self-testing strategies.
Along these lines, an elimination of the need for prescriptions
to obtain self-testing is fundamentally necessary; currently, prescriptions add an additional access barrier. In addition, research
is needed to examine COVID-19 self-testing training materials
that rely too heavily on graphic and written instructions and test
the cultural appropriateness of these materials for low-income
Latino, American Indian/Alaska Native, Native Hawaiian/
Pacifc Islander, or African American populations. Lastly, expensive tests that require mailing specimens to a laboratory for
processing have reduced utility because individuals may not
take necessary preventative precautions while they are awaiting
their test results. Full at-home self-tests that are available at
relatively low costs are required. Ideally, these costs should be
underwritten with by the US government.

Limitations of full at-home test kits may include (1) the
failure to report results to public health authorities and (2) the
inability of antibody-based tests to identify recent active infections. Despite these potential limitations, self-testing is not a
trivial convenience, it is a necessity. Understanding the entire
translation pipeline from test production to dissemination and
implementation in real-world settings is required for testing
systems to be successful [6].
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